UCB stock keeps BIMZELX lead ahead of ACR Convergence data
Published on 11/10/2026 at 11:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSClinical Data Supports BIMZELX Momentum
- BIMZELX achieved an ACR50 response in 54.9% of patients at Week 24, compared with 43.8% for risankizumab.
- The Week 24 findings are part of UCB's wider ACR Convergence program covering 18 abstracts across immunology indications.
- Localized Candida infections were more frequent with BIMZELX, while overall treatment-emergent adverse events were comparable.
UCB's BIMZELX strengthened its clinical case in psoriatic arthritis ahead of a full data presentation at ACR Convergence on Tuesday, November 10. In a company release published Monday, November 9, UCB said the treatment maintained numerically stronger joint responses than risankizumab through Week 24.
According to UCB, 54.9% of patients receiving BIMZELX achieved an ACR50 response at Week 24, versus 43.8% for risankizumab. ACR50 measures at least a 50% improvement in tender and swollen joint counts alongside improvements in three of five additional disease measures.
Week 24 Results Extend Earlier Lead
The result builds on the study's primary Week 16 endpoint. At that earlier assessment, 49.1% of patients on BIMZELX achieved ACR50, compared with 38.0% on risankizumab, a difference of 11.1 percentage points that UCB said was statistically significant.
At Week 24, however, the ACR50 comparison is described as an exploratory endpoint. UCB reported numerically higher BIMZELX responses at every study time point, while the secondary endpoints remained numerically higher but did not reach statistical significance. The first ranked secondary endpoint, minimal disease activity at Week 16, was 3.4 percentage points higher with BIMZELX, but sequential testing stopped at that point.
The BE BOLD Phase 3b trial enrolled 553 adults with active psoriatic arthritis. Participants were either biologic-naive or had previously received one tumor necrosis factor inhibitor without adequate response or with intolerance. The study compared BIMZELX with risankizumab in a randomized, double-blind design through Week 24.
Safety Remains Part Of The Debate
UCB said overall treatment-emergent adverse events were comparable between the two groups. Localized Candida infections occurred more often among BIMZELX-treated patients, at 2.9% versus 0.7% for risankizumab; all reported cases were mild or moderate and none led to treatment discontinuation.
The data add support to UCB's immunology franchise, but they do not remove the need to distinguish between statistically established outcomes and exploratory comparisons. For investors, the commercial significance will depend on whether the additional efficacy signal translates into prescribing momentum against established rivals and whether the safety profile remains manageable in broader use.
Presentation Is The Next Catalyst
The full Week 24 findings are scheduled for an oral presentation at 10:15 a.m. Eastern Time on Tuesday, November 10, at ACR Convergence in Orlando. UCB said its broader presence at the meeting includes 18 abstracts covering psoriatic arthritis, axial spondyloarthritis, rheumatoid arthritis and systemic lupus erythematosus.
UCB stock traded at 298.70 euros on Lang & Schwarz at 11:20 CET on Tuesday, November 10. The quote provides a current market reference while the clinical presentation remains the next scheduled event for investors.
UCB stock at a glance
- Company: UCB S.A.
- ISIN: BE0003739530
- Primary listing: Euronext Brussels, UCB
- Lang & Schwarz quote: 298.70 euros at 11:20 CET on Tuesday, November 10, 2026
- Clinical focus: BIMZELX in psoriatic arthritis
European healthcare shares remain sensitive to trial readouts, regulatory milestones and product launches; see the latest Euro Stoxx 50 market coverage.
